Global healthcare company Johnson & Johnson has reached a $1 billion deal with the US government fo…

Up to 60,000 volunteers will be enrolled in the trial at up to nearly 215 clinical research si…

The deal values Momenta at $52.50 per share, a 70.4% premium to its Wednesday close. The deal is ex…

The drug, esketamine, sold as Spravato, is the first shown to ease depressive symptoms within 24 ho…

By 2050, between 383 million and 725 million more individuals may be exposed to diseases that are s…

Opioid distributors McKesson, Cardinal Health, and AmerisourceBergen all fell as much as 7% in earl…

First reported by the Washington Post, the previously undisclosed company data supplied to the Drug…

Since a number of its executives, including a former CEO, were arrested last December, Insys has be…

This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its C…

A new generation of treatments promises to help more people with depression.

New York, Nov 16 (IANS) Drugmaker Johnson & Johnson has launched the Phase 3 trials of the two-dose…

Johnson & Johnson is in talks with the US National Institute of Health to start the late sta…

Johnson & Johnson's COVID-19 vaccine is being developed by its Janssen pharmaceutical unit and is i…

COVID-19 booster shots should be available in the coming days for everyone who's had J&J, as well a…

He also suggested that for seniors covered by the government's Medicare program, a portion of disco…

While pharmaceutical companies rush to develop their life-saving vaccines, cargo carriers are geari…

Johnson & Johnson published a report on Monday detailing its average list price compared to its…

Attorneys for Murray, however, argued there was evidence Johnson & Johnson "knew that there was…

Jennifer Tauber, executive at Johnson & Johnson's Janssen unit : "Yes we're supportive, and tha…

The US spent an estimated $344.5 billion on prescription drugs in 2018, and the figure is expected …